Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sunshine Biopharma (SBFM) Gross Margin (2018 - 2025)

Historic Gross Margin for Sunshine Biopharma (SBFM) over the last 8 years, with Q3 2025 value amounting to 32.64%.

  • Sunshine Biopharma's Gross Margin fell 13400.0% to 32.64% in Q3 2025 from the same period last year, while for Sep 2025 it was 33.01%, marking a year-over-year increase of 22300.0%. This contributed to the annual value of 30.6% for FY2024, which is 40200.0% down from last year.
  • Latest data reveals that Sunshine Biopharma reported Gross Margin of 32.64% as of Q3 2025, which was down 13400.0% from 36.37% recorded in Q2 2025.
  • Over the past 5 years, Sunshine Biopharma's Gross Margin peaked at 64.98% during Q2 2021, and registered a low of 25.33% during Q2 2024.
  • In the last 5 years, Sunshine Biopharma's Gross Margin had a median value of 35.12% in 2023 and averaged 39.98%.
  • As far as peak fluctuations go, Sunshine Biopharma's Gross Margin tumbled by -346500bps in 2021, and later skyrocketed by 110500bps in 2025.
  • Quarter analysis of 5 years shows Sunshine Biopharma's Gross Margin stood at 28.0% in 2021, then surged by 35bps to 37.85% in 2022, then decreased by -12bps to 33.44% in 2023, then decreased by -4bps to 32.24% in 2024, then increased by 1bps to 32.64% in 2025.
  • Its Gross Margin stands at 32.64% for Q3 2025, versus 36.37% for Q2 2025 and 30.67% for Q1 2025.